Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient

• Published in: Medicina (Kaunas, Lithuania) Vol. 58; no. 10; p. 1354
• Main Authors: Owczarczyk-Saczonek, Agnieszka, Kasprowicz-Furmańczyk, Marta, Kuna, Jakub, Klimek, Paulina, Krajewska-Włodarczyk, Magdalena
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-09-2022; MDPI
• Subjects: Abscess; Abscesses; adalimumab; Antibiotics; Asepsis; aseptic abscess syndrome; Blood; Care and treatment; Case Report; Complications and side effects; Corticosteroids; Diagnosis; Dosage and administration; Fever; Fistula; Gene mutations; Health aspects; Laboratories; Lungs; Monoclonal antibodies; Mutation; Neutrophils; Prevention; Rheumatoid arthritis; Risk factors; Sepsis; Severe acute respiratory syndrome coronavirus 2; Skin diseases; TNF inhibitors; Ulcers; Wrist; Poland
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina58101354

Aseptic abscess syndrome (AAS) is a rare, potentially life-threatening disorder, with numerous features of neutrophilic dermatoses. The main symptoms include aseptic abscess-like collections in internal organs (spleen, liver, lungs), lack of microbes (bacteria, viruses, or parasites) after an exhaustive search, ineffectiveness of antibiotics, and high sensitivity to corticosteroid therapy. AAS is characterized by the development of deep, inflammatory abscesses and systemic symptoms (weight loss, abdominal pain, fever, and leukocytosis). They may be associated with inflammatory bowel disease (IBD) and autoimmune diseases. The patient in this study is a 67-year-old man, suffering from rheumatoid arthritis (RA), with numerous purulent abscesses in the mediastinum, within the subcutaneous tissue above the extension surfaces of the joints, and on the dorsum of the hands. The lesions are accompanied by bone destruction. The patient was treated with prednisone 40 mg and adalimumab, which resulted in a quick reduction of inflammatory markers and clinical improvement, as well as the healing and absorption of abscesses. Despite COVID-19 infection, treatment with remdesivir, prednisone, and adalimumab was continued, with the complete resolution of the lesions. AAS is difficult to recognize, so practitioners have to be aware of this condition, especially in patients with RA.